Expertise in
5
conditions

Dr. Haresh S. Jhangiani

Internal Medicine
Aliso Viejo, CA 
On Staff At
Offers Telehealth
48 Years of Experience
Expertise in
5
conditions
Aliso Viejo, CA 

Overview

Haresh Jhangiani is an Internal Medicine provider practicing medicine in Aliso Viejo, California. He has been practicing medicine for over 48 years.

Dr. Jhangiani is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, and Angiosarcoma.

Dr. Jhangiani is board certified in American Board Internal Medicine. He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 26 clinical trials.

Graduate Institution

Bombay University , 1978 - 1978, 1978

Residency

Kaiser Foundation Hospital , Internal Medicine , 1983 - 1984

Specialties

Internal Medicine

Licenses

Specialist in CA

Board Certifications

American Board Internal Medicine

Fellowships

University of So. California Los Angeles Keck Med. , Medical Oncology , 1987 - 1988

Hospital Affiliations

Memorialcare Orange Coast Medical Center
Uci Health-Orange
Corona Regional Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Inland Empire Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Oncology Physicians Network Of California Pc
Aliso Viejo, CA 92656
Other Locations
Compassionate Cancer Care Medical Group Inc.
11180 Warner Ave, Fountain Valley, CA 92708

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

26 Clinical Trials

An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)
Enrollment Status: Active_not_recruiting
Publish Date: March 18, 2026
Intervention Type: Drug
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 4
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
Enrollment Status: Active_not_recruiting
Publish Date: February 27, 2026
Intervention Type: Drug
Study Drugs: Tepotinib, Osimertinib
Study Phase: Phase 2
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma
Enrollment Status: Terminated
Publish Date: February 18, 2026
Intervention Type: Drug
Study Drug: HMPL-523
Study Phase: Phase 1
An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Enrollment Status: Completed
Publish Date: January 28, 2026
Intervention Type: Drug
Study Drugs: Lasofoxifene, Fulvestrant
Study Phase: Phase 2
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2025
Intervention Type: Drug
Study Drugs: TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel
Study Phase: Phase 1
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Topotecan
Study Phase: Phase 1/Phase 2
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Enrollment Status: Terminated
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drugs: Brentuximab, Doxorubicin, Vinblastine, Dacarbazine, Nivolumab, Filgrastim
Study Phase: Phase 2
A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-689 in Patients With Relapsed or Refractory Lymphoma
A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-689 in Patients With Relapsed or Refractory Lymphoma
Enrollment Status: Terminated
Publish Date: June 26, 2025
Intervention Type: Drug
Study Drug: HMPL-689
Study Phase: Phase 1
CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors
CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: April 03, 2025
Intervention Type: Drug
Study Drug: Seribantumab
Study Phase: Phase 2
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Alpelisib
Study Phase: Phase 3
View 9 Less Clinical Trials

3 Total Publications

Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen.
Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen.
Journal: Experimental hematology
Published: May 02, 2022
Similar Doctors
Expertise in
28
conditions
Dr. Ke-qin Hu
Internal Medicine
Expertise in
28
conditions
Dr. Ke-qin Hu
Internal Medicine

UCI Health

101 The City Dr S, 
Orange, CA 
 (19.1 miles away)
888-717-4463
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ke-qin Hu is an Internal Medicine provider practicing medicine in Orange, California. He has been practicing medicine for over 44 years. Dr. Hu is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Hepatitis, Hepatitis B, Cirrhosis, and Hepatitis C.

Expertise in
29
conditions
Dr. Sant P. Chawla
Internal Medicine
Expertise in
29
conditions
Dr. Sant P. Chawla
Internal Medicine

Cancer Center Of Southern California

2811 Wilshire Blvd, 
Santa Monica, CA 
 (53.5 miles away)
310-552-9999
Experience:
51+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sant Chawla is an Internal Medicine provider practicing medicine in Santa Monica, California. He has been practicing medicine for over 51 years. Dr. Chawla is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, and Myxoid Liposarcoma. Dr. Chawla is board certified in American Board Internal Medicine.

Expertise in
8
conditions
Dr. Behdad Akbarpour
Internal Medicine
Expertise in
8
conditions
Dr. Behdad Akbarpour
Internal Medicine

Behdad Akbarpour MD Inc

Irvine, CA 
 (16.1 miles away)
949-725-0100
Experience:
34+ years
Languages Spoken:
English
See accepted insurances

Behdad Akbarpour is a primary care provider, practicing in Internal Medicine in Irvine, California. He has been practicing medicine for over 34 years. Dr. Akbarpour is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Ethmoiditis, Flu, Cellulitis, and Sinusitis. Dr. Akbarpour is board certified in American Board Of Internal Medicine.

Frequently Asked Questions about Dr. Haresh S. Jhangiani

How do I make an appointment with Dr. Haresh S. Jhangiani?

You can book an appointment with Dr. Haresh S. Jhangiani by calling their office at 714-698-0300. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Haresh S. Jhangiani a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Haresh S. Jhangiani is classified as an Advanced expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Haresh S. Jhangiani specialize in?

While Dr. Haresh S. Jhangiani is a Internal Medicine, they have specific expertise in Breast Cancer, Inflammatory Breast Cancer, and Paget Disease of the Breast. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Haresh S. Jhangiani participate in research or clinical trials?

Yes. Dr. Haresh S. Jhangiani has published 3 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Haresh S. Jhangiani's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Haresh S. Jhangiani accept my insurance?

Dr. Haresh S. Jhangiani accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 714-698-0300 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jhangiani's expertise for a condition
ConditionClose
      View All 92 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile